TABLE OF CONTENTS
Volume 14, Issue 5 (May 2007)
Original Articles
Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells
S Goding, Q Yang, Z Mi, P D Robbins and P H Basse
Cancer Gene Ther 14: 441-450; advance online publication, February 2, 2007; doi:10.1038/sj.cgt.7701019
Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21
T Yamano, Y Kaneda, S H Hiramatsu, S Huang, A N Tran, A E Giuliano and D S B Hoon
Cancer Gene Ther 14: 451-459; advance online publication, February 23, 2007; doi:10.1038/sj.cgt.7701035
Treatment of Implantable NF2 Schwannoma Tumor Models with Oncolytic Herpes Simplex Virus G47
S Prabhakar, S M Messerli, A O Stemmer-Rachamimov, T-C Liu, S Rabkin, R Martuza and X O Breakefield
Cancer Gene Ther 14: 460-467; advance online publication, February 16, 2007; doi:10.1038/sj.cgt.7701037
Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu
M K Magnusson, P Henning, S Myhre, M Wikman, T G Uil, M Friedman, K M E Andersson, S S Hong, R C Hoeben, N A Habib, S Ståhl, P Boulanger and L Lindholm
Cancer Gene Ther 14: 468-479; advance online publication, February 2, 2007; doi:10.1038/sj.cgt.7701027
An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer
X Fu, L Tao and X Zhang
Cancer Gene Ther 14: 480-487; advance online publication, February 9, 2007; doi:10.1038/sj.cgt.7701033
Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors
S Kommareddy and M Amiji
Cancer Gene Ther 14: 488-498; advance online publication, March 16, 2007; doi:10.1038/sj.cgt.7701041
Antitumor activity of dual-specific T cells and influenza virus
A Murphy, J A Westwood, L E Brown, M W L Teng, M Moeller, Y Xu, M J Smyth, P Hwu, P K Darcy and M H Kershaw
Cancer Gene Ther 14: 499-508; advance online publication, March 2, 2007; doi:10.1038/sj.cgt.7701034
Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies
K Rittner, V Schreiber, P Erbs and M Lusky
Cancer Gene Ther 14: 509-518; advance online publication, February 23, 2007; doi:10.1038/sj.cgt.7701036
Letter to the Editor
Potential for stimulating host anti-tumor immune response via RNAi-mediated local FOXP3 knockdown
N Klaiber
Cancer Gene Ther 14: 519-520; advance online publication, March 16, 2007; doi:10.1038/sj.cgt.7701043
